Additionally, insights from the cardiovascular outcome trials of new glucose-lowering drugs, including Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) and Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitors (44–46), indicated a new management strategy on hyperglycemia which focused on clinical outcomes directly instead of just glucose control itself. The gene discussed is GCG; the disease is Hyperglycemia.